These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 38984790)
1. Anticancer activity of Araguspongine C via inducing apoptosis, and inhibition of oxidative stress, inflammation, and EGFR-TK in human lung cancer cells: An in vitro and in vivo study. Li Z; Yu H; Hussain SA; Yang R J Biochem Mol Toxicol; 2024 Jul; 38(7):e23763. PubMed ID: 38984790 [TBL] [Abstract][Full Text] [Related]
2. Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway. Wang H; Du X; Liu W; Zhang C; Li Y; Hou J; Yu Y; Li G; Wang Q Respir Res; 2024 May; 25(1):215. PubMed ID: 38764025 [TBL] [Abstract][Full Text] [Related]
3. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR Wang G; Zhao J; Zhang M; Wang Q; Chen B; Hou Y; Lu K Int J Nanomedicine; 2019; 14():4503-4515. PubMed ID: 31417255 [No Abstract] [Full Text] [Related]
4. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. Diaz R; Nguewa PA; Parrondo R; Perez-Stable C; Manrique I; Redrado M; Catena R; Collantes M; Peñuelas I; Díaz-González JA; Calvo A BMC Cancer; 2010 May; 10():188. PubMed ID: 20459769 [TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer. Galvani E; Giovannetti E; Saccani F; Cavazzoni A; Leon LG; Dekker H; Alfieri R; Carmi C; Mor M; Ardizzoni A; Petronini PG; Peters GJ Neoplasia; 2013 Jan; 15(1):61-72. PubMed ID: 23359111 [TBL] [Abstract][Full Text] [Related]
6. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy. Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220 [TBL] [Abstract][Full Text] [Related]
7. ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models. Kang HN; Kim SH; Yun MR; Kim HR; Lim SM; Kim MS; Hong KW; Kim SM; Kim H; Pyo KH; Park HJ; Han JY; Youn HA; Chang KH; Cho BC Lung Cancer; 2016 May; 95():57-64. PubMed ID: 27040853 [TBL] [Abstract][Full Text] [Related]
8. Pifithrin-μ is efficacious against non-small cell lung cancer via inhibition of heat shock protein 70. Zhou Y; Ma J; Zhang J; He L; Gong J; Long C Oncol Rep; 2017 Jan; 37(1):313-322. PubMed ID: 28004121 [TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin. Zhou X; Qiu J; Wang Z; Huang N; Li X; Li Q; Zhang Y; Zhao C; Luo C; Zhang N; Teng X; Chen Z; Liu X; Yu X; Wu W; Wei YQ; Li J J Cancer Res Clin Oncol; 2012 Jul; 138(7):1081-90. PubMed ID: 22392077 [TBL] [Abstract][Full Text] [Related]
10. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer. Sun C; Gao W; Liu J; Cheng H; Hao J Respir Res; 2020 Aug; 21(1):210. PubMed ID: 32778129 [TBL] [Abstract][Full Text] [Related]
11. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3. Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264 [TBL] [Abstract][Full Text] [Related]
12. Bergamottin isolated from Citrus bergamia exerts in vitro and in vivo antitumor activity in lung adenocarcinoma through the induction of apoptosis, cell cycle arrest, mitochondrial membrane potential loss and inhibition of cell migration and invasion. Wu HJ; Wu HB; Zhao YQ; Chen LJ; Zou HZ Oncol Rep; 2016 Jul; 36(1):324-32. PubMed ID: 27222242 [TBL] [Abstract][Full Text] [Related]
13. Rational design and synthesis of 2,4-dichloro-6-methyl pyrimidine derivatives as potential selective EGFR Duan L; Chu C; Huang X; Yao H; Wen J; Chen R; Wang C; Tu Y; Lv Q; Pan Q; Xu S Arch Pharm (Weinheim); 2024 May; 357(5):e2300736. PubMed ID: 38381049 [TBL] [Abstract][Full Text] [Related]
14. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens. Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325 [TBL] [Abstract][Full Text] [Related]
15. Disruption of NADPH homeostasis by total flavonoids from Adinandra nitida Merr. ex Li leaves triggers ROS-dependent p53 activation leading to apoptosis in non-small cell lung cancer cells. Lan T; He S; Luo X; Pi Z; Lai W; Jiang C; Gan J; Wei S; Wu Z; Yun C; Leng J; Li C J Ethnopharmacol; 2024 Oct; 332():118340. PubMed ID: 38762212 [TBL] [Abstract][Full Text] [Related]
16. Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance. Kim S; Im JH; Kim WK; Choi YJ; Lee JY; Kim SK; Kim SJ; Kwon SW; Kang KW Oxid Med Cell Longev; 2021; 2021():5428364. PubMed ID: 34367462 [TBL] [Abstract][Full Text] [Related]
17. Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer. Kim B; Park YS; Sung JS; Lee JW; Lee SB; Kim YH Cancer Med; 2021 Jan; 10(1):372-385. PubMed ID: 33314735 [TBL] [Abstract][Full Text] [Related]
18. PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations. Dong Q; Yu P; Ye L; Zhang J; Wang H; Zou F; Tian J; Kurihara H Sci Rep; 2019 Apr; 9(1):5692. PubMed ID: 30952931 [TBL] [Abstract][Full Text] [Related]
19. Traditional Chinese medicine Ze-Qi-Tang formula inhibit growth of non-small-cell lung cancer cells through the p53 pathway. Xu Z; Zhang F; Zhu Y; Liu F; Chen X; Wei L; Zhang N; Zhou Q; Zhong H; Yao C; Zhu X; Gong C; Zhu S; Zou C J Ethnopharmacol; 2019 Apr; 234():180-188. PubMed ID: 30660711 [TBL] [Abstract][Full Text] [Related]
20. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells. Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]